BlackRock (NEO holder) discloses 20.4M-share NeoGenomics stake in latest update
BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock. BlackRock reported holding 20,358,331 shares, or 15.6% of the outstanding class. The filing says 19,688,877 shares have sole voting power and 20,358,331 shares have sole dispositive power, and notes iShares Core S&P Small-Cap ETF holds more than 5%.
How this was made
The 30-second read
Why it matters
The key new information is the size of BlackRock’s beneficial ownership (20,358,331 shares, 15.6%) and that it holds sole voting and dispositive power over the shares reported.
Market read
Traders may monitor for follow-on signals (e.g., further accumulation, governance engagement), but the disclosure alone is not a fundamental catalyst.
What to watch
The article does not specify whether the position increased, decreased, or was reclassified; without transaction history, traders may overinterpret the 15.6% figure.
Background
BlackRock filed an amended beneficial ownership report for NeoGenomics common stock, including voting and dispositive power details.
Ticker impact
BlackRock amended its beneficial ownership report showing 20,358,331 NeoGenomics shares, or 15.6% of the class, with sole dispositive power.
Near-term price impact is likely limited unless traders interpret the stake as a signal of increased conviction or upcoming activism.
This is an SEC-style ownership disclosure with control metrics (sole voting and dispositive power) but no new company fundamentals, guidance, or deal terms.
Market effects
Beneficial ownership concentration by a large asset manager can marginally influence sentiment across small-cap healthcare diagnostics, but no sector-wide catalyst is provided.
No direct regional market linkage beyond US small-cap sentiment.
Limited global relevance; the disclosure is US-focused and does not reference international actions.
Counterpoint
A disclosed stake increase or re-reporting may reflect administrative changes or ETF-related holdings rather than a new bullish thesis for NeoGenomics.
Key entities
- public_companyNeoGenomics, Inc.
US-listed company whose common stock beneficial ownership by BlackRock is disclosed.
- public_companyBlackRock, Inc.
Asset manager filing the amended beneficial ownership report.
- fundiShares Core S&P Small-Cap ETF
Referenced as having an interest in NeoGenomics exceeding 5% of outstanding shares.
